Inhaler Device Types for Arformoterol, Budesonide, and Ipratropium-Albuterol
Arformoterol requires a nebulizer, budesonide is available in multiple devices (nebulizer, MDI, or DPI depending on formulation), and ipratropium-albuterol is delivered via either nebulizer or MDI.
Device-Specific Breakdown
Arformoterol
- Device type: Nebulizer only 1
- Arformoterol tartrate inhalation solution (15 mcg/2 mL) is formulated exclusively as a nebulizer solution for twice-daily maintenance treatment of COPD
- This long-acting beta-agonist is not available in MDI or DPI formulations
Budesonide
Multiple device options depending on formulation:
Nebulizer suspension: Budesonide inhalant suspension (0.25-0.5 mg) is the only inhaled corticosteroid with FDA-approved labeling for children <4 years of age 2
- Requires jet nebulizer (ultrasonic nebulizers are ineffective for suspensions)
- Compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions 2
Metered-Dose Inhaler (MDI): Available as HFA-propelled formulation 3
Dry Powder Inhaler (DPI): Mometasone and other corticosteroid formulations available 3
Ipratropium-Albuterol Combination
Two device options:
Nebulizer solution: Each 3 mL vial contains 0.5 mg ipratropium bromide and 3 mg albuterol sulfate (equivalent to 2.5 mg albuterol base) 4
- Clear, colorless solution that does not require dilution
- Should be administered via jet nebulizer connected to air compressor with adequate flow
- Mean delivered dose is approximately 46% of albuterol and 42% of ipratropium with appropriate nebulizer systems 4
- Mean nebulization time is 15 minutes or less
Metered-Dose Inhaler (MDI): Ipratropium HFA formulation available (200 mcg/puff) 2
- Provides 2-3 puffs every 4-6 hours
- HFA-propelled preparation gained marketing approval and is included in dosing charts 3
Important Clinical Considerations
Nebulizer Compatibility
When mixing medications in nebulizers (a common real-world practice):
- Budesonide is compatible with albuterol and ipratropium 2, 5, 1, 6
- Arformoterol is chemically and physically compatible with ipratropium bromide and budesonide for at least 30 minutes 1
- Caveat: While chemical compatibility is established, these studies did not evaluate clinical efficacy or aerosol characteristics of admixtures 1
Device Selection Guidance
According to guidelines 2:
MDI devices require slow inhalation (30 L/min or 3-5 seconds) with 10-second breath-hold
- Coordination of actuation and inhalation may be difficult in young children and elderly
- 50-80% of actuated dose deposits in oropharynx
- Mouth washing and spitting reduces systemic absorption
Nebulizers are preferred when: